Long-term multidrug therapy in an adolescent patient with proliferative lupus nephritis: A trial of less cytotoxic therapy

Clinical Nephrology

Volumn 78, Issue 4, 2012, Pages 332-

  Aizawa Yashiro, Tomomi ^a   Tsuruga, Kazushi ^a   Watanabe, Shojiro ^a   Echizenya, Taketora ^b   Ito, Etsuro ^a   Tanaka, Hiroshi ^a,c  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b Iwate Prefectural Chubu Hospital   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ANTIBODY TITER; CASE REPORT; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG PULSE THERAPY; ELECTRON MICROSCOPY; FEMALE; HEMATURIA; HEMOPHAGOCYTIC SYNDROME; HISTOPATHOLOGY; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LETTER; LONG TERM CARE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; PROLIFERATIVE LUPUS NEPHRITIS; PROTEINURIA; RASH; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUPUS NEPHRITIS; PREDNISOLONE; RIBONUCLEOSIDES; TACROLIMUS;

EID: 84867684414     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107551     Document Type: Letter

References (10)

1. Davidson A, Aranow C. Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol. 2006; 18: 468-475. PubMed
2. Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008; 58: 556-562. doi:10.1002/art.23204 PubMed
3. Tanaka H, Oki E, Tsuruga K, Sato N, Matsukura H, Matsunaga A, Kondo Y, Suzuki J. Mizoribine treatment of young patients with severe lupus nephritis: a clinicopathologic study by the Tohoku Pediatric Study Group. Nephron Clin Pract. 2008; 110: c73-c79. doi:10.1159/000151721 PubMed
4. Aizawa-Yashiro T, Tsuruga K, Watanabe S, Oki E, Ito E, Tanaka H. Novel multidrug therapy for children with cyclosporine-resistant or -intolerant nephrotic syndrome. Pediatr Nephrol. 2011; 26: 1255-1261. doi:10.1007/s00467-011-1876-z PubMed
5. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008; 19: 2001-2010. doi:10.1681/ ASN.2007121272 PubMed
6. Cortés-Hernández J, Torres-Salido MT, Medrano AS, Tarrés MV, Ordi-Ros J. Long-term outcomes - mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant. 2010; 25: 3939-3948. doi:10.1093/ndt/gfq322 PubMed
7. Lanata CM, Mahmood T, Fine DM, Petri M. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lupus. 2010; 19: 935-940. doi:10.1177/0961203310365714 PubMed
8. Hara S, Umino D, Someya T, Fujinaga S, Ohtomo Y, Murakami H, Shimizu T. Protective effects of mizoribine on cyclosporine A nephropathy in rats. Pediatr Res. 2009; 66: 524-527. doi:10.1203/ PDR.0b013e3181b9b48a PubMed
9. Tanaka H, Oki E, Tsuruga K, Aizawa-Yashiro T, Ito Y, Sato N, Kawasaki Y, Suzuki J. Mizoribine attenuates renal injury and macrophage infiltration in patients with severe lupus nephritis. Clin Rheumatol. 2010; 29: 1049-1054. doi:10.1007/ s10067-010-1484-5 PubMed
10. Tanaka H, Oki E, Tsuruga K, Yashiro T, Hanada I, Ito E. Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose. Clin Nephrol. 2009; 72: 430-436. PubMed